🔎 Trials Near Me

Gara Jalqabaatti › Burkitt Lymphoma › Oklahoma

Qorannoo klinikaalii Burkitt Lymphoma Oklahoma keessatti

Qorannoo 7 Burkitt Lymphoma f Oklahoma keessatti hirmaatuu jiru.

Magaalota Oklahoma keessatti

Takkalaa qorannoo (Ingiliffa)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 39 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
365 Days · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Saint Francis Children's Hospital, Tulsa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 1 hanga 30 · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Saint Francis Children's Hospital, Tulsa
Namoota walitti qabaa jiraSadarkaa 3
365 Days – 25 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT03959085

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 31-Ado-2026 · NCT07069699

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.